Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material

Modern Pathology

Volumn 15, Issue 2, 2002, Pages 116-124

  Xu, Ruliang ^a   Perle, Mary Ann ^a   Inghirami, Giorgio ^a   Chan, Wai ^a   Delgado, Yara ^a   Feiner, Helen ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Breast carcinoma; Fluorescent in situ hybridization; Her 2 neu; Immunohistochemistry

Indexed keywords

NEU DIFFERENTIATION FACTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BENIGN TUMOR; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST DUCT; CANCER INVASION; CANCER SURVIVAL; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PRECANCER; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM METASTASIS; PRECANCEROUS CONDITIONS; RECEPTOR, ERBB-2;

EID: 0036180273     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880503     Document Type: Article

References (44)

1. The c-erb B-2 protein in oncogenesis: Molecular structure to molecular epidemiology
2. HER-2/neu (c-erb-B2) gene and protein in breast cancer
3. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer
4. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer
5. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in nodenegative breast carcinomas
6. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer
7. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: Its correlation with sex steroid receptors, cathepsin D and histologic grades
8. C-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples
9. Neu (C-erbB-2) oncogene in breast cancer and its possible association with the risk of distant metastases. A retrospective study and review of literature
10. The combination of in situ hybridization and immunohistochemical analysis: An evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium
11. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast
12. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer
13. C-erbB-2: Expression in patients with breast carcinoma in comparison to patients with benign breast diseases
14. Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions
15. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
16. Expression of c-erb B-2 prptein and DNA ploidy in breast carcinogenesis
17. Amplification of C-ERB-B2 and aggressive breast tumors?
18. Basic sciences of Her-2/neu: A review
19. Active signaling by Neu in transgenic mice
20. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk
21. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
22. Reproducibility of LSI HER-2/neu SpectrumOrange and CEP 17 SpectrumGreen Dual Color deoxyribonucleic acid probe kit. For enumeration of gene amplification in paraffin-embedded specimens: A multicenter clinical validation study
23. A scoring system for immunohistochemical staining: Consensus report of the Task Force for Basic Research the EORTC-GCGC
24. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
25. Study of neuprotein expression in mammary disease
26. Numerical abnormalities of chromosomes 7, 18, and X in precancerous breast disease defined by fluorescent in situ hybridization
27. HER-2/Neu expression as a progression marker in pancreatic intraepithelial neoplasia
28. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues
29. Stability of HER-2/neu expression over time and at multiple metastatic sites
30. HER-2/neu gene in primary and local metastatic axillary lymph nodes in human breast tumors
31. Breast cancer heterogeneity: Evaluation of clonality in primary and metastatic lesions
32. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model
33. The neu-protein and breast cancer
34. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis
35. The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients
36. Prognosis of breast cancer: Evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes
37. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
38. Determination of Her-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization
39. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
40. Quantification of ERBB2 protein expression in breast cancer: Three levels of expression defined by their clinico-pathological correlations
41. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
42. Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein
43. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer